---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-168273"
form_type: "8-K"
ticker: "TECX"
cik: "0001681087"
company_name: "Tectonic Therapeutic, Inc."
filed_at: "2024-06-26T23:59:59+00:00"
generated_at: "2026-06-01T01:38:11.160668+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tectonic Therapeutics details TX45 Phase 2 trial design for Group 2 PH-HFpEF

## Summary
- Phase 2 randomized, placebo-controlled, double-blind trial to start H2 2024 globally (US, Europe, Eastern Europe, Australia).
- Trial enriches for patients with PVR >3 on right heart catheterization; ~180 subjects expected.
- Subjects randomized 1:1:1 to two TX45 doses or placebo; 24-week treatment plus 8-week follow-up.
- Goal: evaluate efficacy in combined pre- and post-capillary PH and whole Group 2 PH-HFpEF population.

## SEC filing metadata
- accession: 0001193125-24-168273
- form_type: 8-K
- ticker: TECX
- cik: 0001681087
- company_name: Tectonic Therapeutic, Inc.
- filed_at: 2024-06-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681087/000119312524168273/0001193125-24-168273-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681087/000119312524168273/d822923d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-168273
- JSON: https://secwatch.observer/filing/0001193125-24-168273.json
- Plain text: https://secwatch.observer/filing/0001193125-24-168273.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.